Glenmark Pharmaceuticals has informed that it attached a media release on September 2021 titled ‘Glenmark concludes post marketing surveillance (PMS) study on Favipiravir (FabiFlu®) in 1000+ COVID-19 patients, findings reinforce the drug’s safety and efficacy in real world settings’.
The above information is a part of company’s filings submitted to BSE.